Literature DB >> 1571993

Intracoronary stent implantation via the brachial approach: a technique to reduce vascular bleeding complications.

R R Heuser1, S S Mehta, R K Strumpf, R Ponder.   

Abstract

To reduce the incidence of vascular complications of intracoronary stent implantation, we used the brachial approach. We attempted implantation of the Palmaz-Schatz stent via the brachial artery approach at 10 lesions in 9 patients. Stent delivery was successful at 8 lesions. Balloon angioplasty was successfully performed in the 2 failed cases, 1 of whom required surgical repair of the brachial artery. Intravenous anticoagulation was uninterrupted from the time of stent placement until therapeutic prothrombin times from oral warfarin therapy were obtained. Neither acute nor long-term major bleeding occurred in the 9 patients. There were no embolic events, myocardial infarctions, or deaths. One subacute thrombosis occurred, and the patient underwent bypass surgery. To evaluate the risks and benefits of the brachial approach, we compared these 9 patients with 41 who had stent placement by the femoral approach during the same period. Lesion characteristics were similar in these 2 groups. There were no significant differences in the success rate or angiographic outcome between the 2 groups. Seven (17%) patients in the femoral group had vascular access complications requiring surgery, compared with 1 (11%) in the brachial group. No patient in the brachial group required transfusion, compared with all 7 of the patients who had femoral vascular complications. The potential reduction in bleeding complications makes the brachial approach to stent implantation attractive in selected patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1571993     DOI: 10.1002/ccd.1810250409

Source DB:  PubMed          Journal:  Cathet Cardiovasc Diagn        ISSN: 0098-6569


  1 in total

1.  Outpatient coronary angiography: indications, safety, and complication rates.

Authors:  R R Heuser
Journal:  Herz       Date:  1998-02       Impact factor: 1.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.